The clinical study of the activated self-lymphocytes introduction therapy using a self-tumor (tissue) and a dendritic cells for a relapse and a advanced cancer.

The clinical study of the activated self-lymphocytes introduction therapy using a self-tumor (tissue) and a dendritic cells for a relapse and a advanced cancer. - The clinical study of the activated self-lymphocytes introduction therapy using a self-tumor (tissue) and a dendritic cells for a relapse and a advanced cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006276

Enrollment

Registered

2011-09-05

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapse and advanced cancer

Interventions

Activated self-lymphocytes

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patients that the diagnosis of the cancer was obtained by histological diagnosis or cytodiagnosis. 2)An outpatients over 20 years old. 3) Performance States (P.S.) is 0 to 3. 4) The good prognosis will be expected 3 months or more until administration starting point. 5) In principle, keep major organ function is kept as follows; Number of White Blood Cell>4,000/mm3, <12,000/mm3. Number of neutrophil>2,000/mm3. Platelet count>100,000/mm3. Number of hemoglobin>10.0g/dL. Serum GOP and GPT< upper limits of institution x 2. Total serum bilirubin<1.5mg/dL. Serum creatinine<1.5mg//dL. But in the case of not meet a condition, reason came from existing diseasey(Cancer). Lead principal investigator can add those patients to this study by his judgment. 6) The patient that agreement was obtained in a document than the person himself in response to a name of disease condition notice. 7) Women; Pregnant possibility is denied by surgery, radiation or menopause, or possibility of pregnant can be reduced by the use of the approved antifertility method from the administration starting point to after 3 month of study finished.

Exclusion criteria

Exclusion criteria: 1) The patients with autoimmune disease 2) The patients with complications having poor control. (An infection, diabetes, hypertension, ischemic heart disease, cerebral infraction, etc.). 3) The patients egnancy nursing mother and the pregnant likelihood(possibility). 4) The patients history of the drug allergy. 5) Other, the patients is judged inadequate by research contact person.

Design outcomes

Primary

Measure	Time frame
Establishment of the procedure, verification of tolerability and safety of "the activated self-lymphocytes introduction therapy using a self-tumor (tissue) and dendritic cells.	—

Secondary

Measure	Time frame
QOL, A cytoreductive effect and a prognosis prolongation effect.	—

Countries

Japan

Contacts

Public ContactAtsushi Ochiai

Tomishiro Central Hospital Office of Clinical Trial

ochiai.tomishirocentral.hp@gmail.com098-851-8131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026